TScan is dedicated to changing lives by discovering new cancer targets and developing safe and effective T-cell therapies for patients.
Within the tumors of cancer patients are T cells with the ability to recognize and eliminate cancer cells. We are using our proprietary target ID platform to identify the natural targets of tumor-reactive T cells and identify therapeutically active TCRs that are both safe and effective.
TScan’s experienced leadership team shares the goal of delivering groundbreaking cancer treatments to patients.
For more information about TScan, career or collaboration opportunities.
General Partner at Longwood Fund
CEO of TScan Therapeutics
Founder of Sepracor
Managing General Partner with Pitango Venture Capital
Investor at Bessemer Venture Partners
Principal at Novartis Venture Fund
CFO and Head of Corporate Development at Freeline
CFO of Nodthera